Latest news
The Oral GLP-1 Tracker: Lilly's Foundayo builds scripts after disappointing Q2 - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 07:00:00 GMTLilly Files Its GLP-1 Pill for Diabetes, and the Manufacturing Case Is Stronger Than the Access Case - Medical DailyMedical Daily · Thu, 06 Aug 2026 12:00:14 GMTOral GLP-1 drugs may turn down the brain’s food craving circuit - diabetes.co.ukdiabetes.co.uk · Thu, 06 Aug 2026 02:17:24 GMTNovo lifts outlook as oral Wegovy surges in US and widens GLP-1 lead - CHOSUNBIZ - ChosunbizChosunbiz · Thu, 06 Aug 2026 01:38:00 GMTLLY Looks 19.8% Undervalued on GF Value™ as Oral GLP-1 Sales Imp - GuruFocusGuruFocus · Thu, 06 Aug 2026 00:29:15 GMTLilly outperforms in bid to unseat Novo’s lead in oral GLP-1 market - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 18:48:44 GMTLilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 - BioSpaceBioSpace · Wed, 05 Aug 2026 13:39:37 GMTNew Weight Loss Medication: What the 2026 Oral GLP-1 Options Really Deliver *i1Z548IJH* - Diario ASDiario AS · Wed, 05 Aug 2026 00:19:08 GMT